164 related articles for article (PubMed ID: 25560576)
21. Combined molecular dynamics and continuum solvent approaches (MM-PBSA/GBSA) to predict noscapinoid binding to γ-tubulin dimer.
Suri C; Naik PK
SAR QSAR Environ Res; 2015 Jun; 26(6):507-19. PubMed ID: 26274780
[TBL] [Abstract][Full Text] [Related]
22. CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism.
Yang Y; Ran J; Sun L; Sun X; Luo Y; Yan B; Tala ; Liu M; Li D; Zhang L; Bao G; Zhou J
Theranostics; 2015; 5(7):656-66. PubMed ID: 25897332
[TBL] [Abstract][Full Text] [Related]
23. Molecular insight of isotypes specific β-tubulin interaction of tubulin heterodimer with noscapinoids.
Santoshi S; Naik PK
J Comput Aided Mol Des; 2014 Jul; 28(7):751-63. PubMed ID: 24916062
[TBL] [Abstract][Full Text] [Related]
24. In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin).
Naik PK; Lopus M; Aneja R; Vangapandu SN; Joshi HC
J Comput Aided Mol Des; 2012 Feb; 26(2):233-47. PubMed ID: 22170255
[TBL] [Abstract][Full Text] [Related]
25. Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation.
Mishra RC; Karna P; Gundala SR; Pannu V; Stanton RA; Gupta KK; Robinson MH; Lopus M; Wilson L; Henary M; Aneja R
Biochem Pharmacol; 2011 Jul; 82(2):110-21. PubMed ID: 21501599
[TBL] [Abstract][Full Text] [Related]
26. Rational design of 9-vinyl-phenyl noscapine as potent tubulin binding anticancer agent and evaluation of the effects of its combination on Docetaxel.
Dash SG; Suri C; Nagireddy PKR; Kantevari S; Naik PK
J Biomol Struct Dyn; 2021 Sep; 39(14):5276-5289. PubMed ID: 32608323
[TBL] [Abstract][Full Text] [Related]
27. Noscapinoids with anti-cancer activity against human acute lymphoblastic leukemia cells (CEM): a three dimensional chemical space pharmacophore modeling and electronic feature analysis.
Naik PK; Santoshi S; Joshi HC
J Mol Model; 2012 Jan; 18(1):307-18. PubMed ID: 21523542
[TBL] [Abstract][Full Text] [Related]
28. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Lopus M; Oroudjev E; Wilson L; Wilhelm S; Widdison W; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2689-99. PubMed ID: 20937594
[TBL] [Abstract][Full Text] [Related]
29. Noscapine and its Analogs as Chemotherapeutic Agent: Current updates.
Tomar V; Kukreti S; Prakash S; Madan J; Chandra R
Curr Top Med Chem; 2017; 17(2):174-188. PubMed ID: 27237331
[TBL] [Abstract][Full Text] [Related]
30. Recent patents reveal microtubules as persistent promising target for novel drug development for cancers.
Bughani U; Li S; Joshi HC
Recent Pat Antiinfect Drug Discov; 2009 Nov; 4(3):164-82. PubMed ID: 19673697
[TBL] [Abstract][Full Text] [Related]
31. A new antiproliferative noscapine analogue: chemical synthesis and biological evaluation.
Ghaly PE; Abou El-Magd RM; Churchill CD; Tuszynski JA; West FG
Oncotarget; 2016 Jun; 7(26):40518-40530. PubMed ID: 27777381
[TBL] [Abstract][Full Text] [Related]
32. Implications of nanoscale based drug delivery systems in delivery and targeting tubulin binding agent, noscapine in cancer cells.
Chandra R; Madan J; Singh P; Chandra A; Kumar P; Tomar V; Dass SK
Curr Drug Metab; 2012 Dec; 13(10):1476-83. PubMed ID: 22571485
[TBL] [Abstract][Full Text] [Related]
33. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma.
Landen JW; Lang R; McMahon SJ; Rusan NM; Yvon AM; Adams AW; Sorcinelli MD; Campbell R; Bonaccorsi P; Ansel JC; Archer DR; Wadsworth P; Armstrong CA; Joshi HC
Cancer Res; 2002 Jul; 62(14):4109-14. PubMed ID: 12124349
[TBL] [Abstract][Full Text] [Related]
34. The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and its Clinical Applications.
Rida PC; LiVecche D; Ogden A; Zhou J; Aneja R
Med Res Rev; 2015 Sep; 35(5):1072-96. PubMed ID: 26179481
[TBL] [Abstract][Full Text] [Related]
35. Noscapine, a Non-addictive Opioid and Microtubule-Inhibitor in Potential Treatment of Glioblastoma.
Altinoz MA; Topcu G; Hacimuftuoglu A; Ozpinar A; Ozpinar A; Hacker E; Elmaci İ
Neurochem Res; 2019 Aug; 44(8):1796-1806. PubMed ID: 31292803
[TBL] [Abstract][Full Text] [Related]
36. Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
DeBono A; Capuano B; Scammells PJ
J Med Chem; 2015 Aug; 58(15):5699-727. PubMed ID: 25811651
[TBL] [Abstract][Full Text] [Related]
37. Novel 9'-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation.
Porcù E; Sipos A; Basso G; Hamel E; Bai R; Stempfer V; Udvardy A; Bényei AC; Schmidhammer H; Antus S; Viola G
Eur J Med Chem; 2014 Sep; 84():476-90. PubMed ID: 25050880
[TBL] [Abstract][Full Text] [Related]
38.
Meher RK; Nagireddy PKR; Pragyandipta P; Kantevari S; Singh SK; Kumar V; Naik PK
J Biomol Struct Dyn; 2022 Sep; 40(15):6725-6736. PubMed ID: 33627059
[TBL] [Abstract][Full Text] [Related]
39. Insight into the Tubulin-Targeted Anticancer Potential of Noscapine and its Structural Analogs.
Kumar S; Sagar B; Gaur A; Shukla S; Pandey E; Gulati S
Anticancer Agents Med Chem; 2023; 23(6):624-641. PubMed ID: 35927808
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of N-substituted noscapine analogues.
DeBono AJ; Xie JH; Ventura S; Pouton CW; Capuano B; Scammells PJ
ChemMedChem; 2012 Dec; 7(12):2122-33. PubMed ID: 23055449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
